Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Change in Accured Expenses (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Change in Accured Expenses data on record, last reported at $692000.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 129.9% year-over-year to $692000.0; the TTM value through Dec 2025 reached $2.0 million, up 146.08%, while the annual FY2025 figure was $2.0 million, 146.08% up from the prior year.
  • Change in Accured Expenses reached $692000.0 in Q4 2025 per TLSI's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2023 and bottomed at -$4.6 million in Q3 2023.
  • Average Change in Accured Expenses over 4 years is $357500.0, with a median of $257864.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: crashed 1486.36% in 2024, then skyrocketed 632.46% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $4.1 million in 2022, then surged by 30.69% to $5.4 million in 2023, then tumbled by 94.43% to $301000.0 in 2024, then soared by 129.9% to $692000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $692000.0 in Q4 2025, $1.5 million in Q3 2025, and -$1.8 million in Q2 2025.